{
    "Trade/Device Name(s)": [
        "BGM014 Blood Glucose Monitoring System",
        "BGM014 Pro Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Apex Biotechnology Corp.",
    "510(k) Number": "K161299",
    "Predicate Device Reference 510(k) Number(s)": [
        "K131750"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW",
        "LFR",
        "JJX"
    ],
    "Summary Letter Date": "November 30, 2016",
    "Summary Letter Received Date": "December 5, 2016",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1345",
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Glucose test system",
        "Single (specified) analyte controls (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Capillary whole blood",
        "Venous whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BGM014 Blood Glucose Meter",
        "BGM014 Pro Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strip",
        "Control Solution"
    ],
    "Document Summary": "FDA 510(k) summary for BGM014 and BGM014 Pro Blood Glucose Monitoring Systems for quantitative glucose measurement in capillary and venous whole blood.",
    "Indications for Use Summary": "Intended for quantitative measurement of glucose in whole blood; BGM014 for self-testing by diabetics at home using capillary blood; BGM014 Pro for multiple-patient use in professional healthcare settings using capillary or venous blood, as an aid to monitor diabetes control effectiveness; not for diagnosis, screening, or neonatal use.",
    "fda_folder": "Clinical Chemistry"
}